These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 11575704)

  • 1. TAK-779 (Takeda).
    Esté JA
    Curr Opin Investig Drugs; 2001 Mar; 2(3):354-6. PubMed ID: 11575704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice.
    van Wanrooij EJ; Happé H; Hauer AD; de Vos P; Imanishi T; Fujiwara H; van Berkel TJ; Kuiper J
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2642-7. PubMed ID: 16239591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
    Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
    Baba M; Takashima K; Miyake H; Kanzaki N; Teshima K; Wang X; Shiraishi M; Iizawa Y
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4584-91. PubMed ID: 16251299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5.
    Hall SE; Mao A; Nicolaidou V; Finelli M; Wise EL; Nedjai B; Kanjanapangka J; Harirchian P; Chen D; Selchau V; Ribeiro S; Schyler S; Pease JE; Horuk R; Vaidehi N
    Mol Pharmacol; 2009 Jun; 75(6):1325-36. PubMed ID: 19297521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis.
    Tokuyama H; Ueha S; Kurachi M; Matsushima K; Moriyasu F; Blumberg RS; Kakimi K
    Int Immunol; 2005 Aug; 17(8):1023-34. PubMed ID: 16000328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diverse modifications of the 4-methylphenyl moiety of TAK-779 by late-stage Suzuki-Miyaura cross-coupling.
    Junker A; Schepmann D; Yamaguchi J; Itami K; Faust A; Kopka K; Wagner S; Wünsch B
    Org Biomol Chem; 2014 Jan; 12(1):177-86. PubMed ID: 24217712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BMS-232632 (Novartis/Bristol-Myers Squibb).
    Witherell G
    Curr Opin Investig Drugs; 2001 Mar; 2(3):340-7. PubMed ID: 11575702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of blocking the chemokine receptors, CCR5 and CXCR3, With TAK-779 in a rat small intestinal transplantation model.
    Xu H; Firdawes S; Yamamoto A; Zhao Y; Ihara Y; Uehara S; Matsunami K; Otsuka H; Fukuzawa M; Miyagawa S
    Transplantation; 2008 Dec; 86(12):1810-7. PubMed ID: 19104427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.
    Shiraishi M; Aramaki Y; Seto M; Imoto H; Nishikawa Y; Kanzaki N; Okamoto M; Sawada H; Nishimura O; Baba M; Fujino M
    J Med Chem; 2000 May; 43(10):2049-63. PubMed ID: 10821717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
    Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
    J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies.
    Dhami H; Fritz CE; Gankin B; Pak SH; Yi W; Seya MJ; Raffa RB; Nagar S
    J Clin Pharm Ther; 2009 Apr; 34(2):147-60. PubMed ID: 19250135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Building three-dimensional structures of HIV-1 coreceptor CCR5 and its interaction with antagonist TAK779 by comparative molecular modeling.
    Huang XQ; Jiang HL; Luo XM; Chen KX; Ji RY; Cao Y; Pei G
    Acta Pharmacol Sin; 2000 Jun; 21(6):521-8. PubMed ID: 11360686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel (S)-alpha-phenyl-gamma-amino butanamide containing CCR5 antagonists via functionality inversion approach.
    Zhang HS; Feng DZ; Chen L; Long YQ
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2219-23. PubMed ID: 20207141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brasofensine NeuroSearch.
    Yu P
    Curr Opin Investig Drugs; 2000 Dec; 1(4):504-7. PubMed ID: 11249705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
    Princen K; Schols D
    Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept Immunex.
    Yung RL
    Curr Opin Investig Drugs; 2001 Feb; 2(2):216-21. PubMed ID: 11816834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exubera. Inhale therapeutic systems.
    Bindra S; Cefalu WT
    Curr Opin Investig Drugs; 2002 May; 3(5):758-62. PubMed ID: 12090549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a chemokine network that recruits FoxP3(+) regulatory T cells into chronically inflamed intestine.
    Kang SG; Piniecki RJ; Hogenesch H; Lim HW; Wiebke E; Braun SE; Matsumoto S; Kim CH
    Gastroenterology; 2007 Mar; 132(3):966-81. PubMed ID: 17324406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density.
    Willey S; Peters PJ; Sullivan WM; Dorr P; Perros M; Clapham PR
    Antiviral Res; 2005 Nov; 68(2):96-108. PubMed ID: 16157392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.